Puma Biotechnology Inc (PBYI)

pos +3.80
Today's Range: 102.65 - 108.75 | PBYI Avg Daily Volume: 909,500
Last Update: 09/20/17 - 12:36 PM EDT
Volume: 334,623
YTD Performance: 241.86%
Open: $102.65
Previous Close: $103.40
52 Week Range: $28.35 - $109.85
Oustanding Shares: 37,205,597
Market Cap: 3,904,727,405
6-Month Chart
TheStreet Ratings Grade for PBYI
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 5 5 4
Moderate Buy 0 0 0 0
Hold 1 1 1 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.29 1.33 1.33 1.40
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -12.89
Price Earnings Comparisons:
PBYI Sector Avg. S&P 500
-12.89 0.00 36.80
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
34.72% 73.90% -61.85%
Revenue 0.00 0.00 0.00
Net Income 0.00 4.00 0.00
EPS 0.00 3.40 0.00
Earnings for PBYI:
Revenue 0.00B
Average Earnings Estimates
Qtr (09/17) Qtr (12/17) FY (12/17) FY (12/18)
Average Estimate $-2.71 $-2.06 $-8.92 $-4.30
Number of Analysts 4 3 4 4
High Estimate $-2.02 $-2.00 $-8.10 $1.06
Low Estimate $-4.28 $-2.17 $-10.54 $-9.01
Prior Year $-2.02 $-2.04 $-8.29 $-8.92
Growth Rate (Year over Year) -33.91% -1.14% -7.60% 51.85%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
Despite the good action in the indices, I'm not putting much money to work.
These stocks are showing signs of changing direction.
Shares are finally roaring back from big losses in 2014 and 2015.
General Electic shares dipped as industrial orders waned in the second quarter.
Mar 29, 2016 | 7:38 AM EDT
PBYI was downgraded to Sector Perform, RBC Capital said. $36 price target. Company is again pushing out the timeline for ExteNET, as th...

Stocks Trade Near Session Lows Real Money Pro($)

Puma Biotechnology (PBYI) has become the latest in a myriad of small-cap biotech stocks to see big declines. The stock has tanked after announcing disappointing trial results for its main drug candidate. Small-caps across the sector are getting hit hard in sympathy as sentiment moves back to full "risk-off" mode. The U.S. House has passed a bill to keep the federal government funded into next week. Hopefully, this latest funding fight gets resolved amicably. The last thing the market needs is yet another headwind. It's going to be a very interesting final few hours of the trading week. Do we some recovery or does the sell-off accelerate? Your guess is as good as mine at this point.
Mixing growth-oriented investing with value outperforms.
When we do see a dip, don't expect it to last for long.
In theory there should be plenty of shorting opportunities.
Too many people are willing to park cash in Microsoft or Apple.

Columnist Conversations

The symmetry is holding up in MCD.  Target 1 is 163.34 if we continue to hold above here!  ...
As far as TSLA is concerned, I still have a higher target above the market at the 409 area.  I stated in ...
The TLT setup discussed in my last commentary is a bust. Key support was violated and it violated the recent l...
BBY is getting smoked this mornings(weak forecast).  The stock is off 8% after opening the session with a...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.